These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 19473110)

  • 1. An exploratory analysis of the cost-effectiveness of insulin glargine 300 units/mL versus insulin glargine 100 units/mL over a lifetime horizon using the BRAVO diabetes model.
    Shao H; Shi L; Fonseca V; Alsaleh AJO; Gill J; Nicholls C
    Diabet Med; 2024 May; 41(5):e15303. PubMed ID: 38470100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review.
    Hagenmeyer EG; Koltermann KC; Dippel FW; Schädlich PK
    Cost Eff Resour Alloc; 2011 Oct; 9(1):15. PubMed ID: 21978524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost and utilization comparisons among propensity score-matched insulin lispro and regular insulin users.
    Hall JA; Summers KH; Obenchain RL
    J Manag Care Pharm; 2003; 9(3):263-8. PubMed ID: 14613470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budget Impact Analysis of the FreeStyle Libre Flash Continuous Glucose Monitoring System
    Palacios A; Rodriguez-Cairoli F; Balan D; Rojas-Roque C; Moreno-López C; Braun B; Augustovski F; Pichon-Riviere A; Bardach A
    Appl Health Econ Health Policy; 2023 Jul; 21(4):637-650. PubMed ID: 37062046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The direct cost of intravenous insulin infusions to the NHS in England and Wales.
    Rajendran R; Scott A; Rayman G
    Clin Med (Lond); 2015 Aug; 15(4):330-3. PubMed ID: 26407380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Type 2 diabetes in Andalusia: Resources use and economic cost].
    Aguirre Rodríguez JC; Sánchez Cambronero M; Guisasola Cárdenas M; Generoso Torres MN; Hidalgo Rodríguez A; Martín Enguix D; González Bravo A
    Semergen; 2023; 49(8):102066. PubMed ID: 37517163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical courses and costs for hospitalizations of potentially immunocompromised COVID-19 patients in Germany].
    Häckl D; Pignot M; Dang PL; Lauenroth V; Jah F; Wendtner CM
    Dtsch Med Wochenschr; 2024 Mar; 149(7):e38-e46. PubMed ID: 38479416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cost of Managing Type 2 Diabetes Mellitus in Greece: A Retrospective Analysis of 10-Year Patient Level Data "The HERCULES Study".
    Migdalis I; Rombopoulos G; Hatzikou M; Manes C; Kypraios N; Tentolouris N
    Int J Endocrinol; 2015; 2015():520759. PubMed ID: 26089887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes Technology and Waste: A Real-World Study in a Specialized Practice in Germany.
    Petry SF; Petry FW; Petry JK; Gäth S; Heinemann L
    J Diabetes Sci Technol; 2024 Jun; ():19322968241257004. PubMed ID: 38840530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of the enhanced COVID-19 surveillance during UEFA EURO 2020 in Germany.
    Heese H; Marquis A; Diercke M; Markus I; Böhm S; Metz J; Katz K; Wildner M; Liebl B
    Epidemiol Infect; 2022 Mar; 150():1-18. PubMed ID: 35236530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment.
    Gallwitz B; Bretzel RG
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S180-9. PubMed ID: 23882044
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of insulin use and value for money in type 2 diabetes in the United kingdom.
    Gordon J; Evans M; McEwan P; Bain S; Vora J
    Diabetes Ther; 2013 Jun; 4(1):51-66. PubMed ID: 23296753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of treatment costs in inadequately controlled type 2 diabetes in Germany based on the APOLLO trial with insulin glargine.
    Bretzel RG; Dippel FW; Linn T; Neilson AR
    J Med Econ; 2009 Jun; 12(2):87-97. PubMed ID: 19473110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany.
    Pscherer S; Dietrich ES; Dippel FW; Neilson AR
    Int J Clin Pharmacol Ther; 2010 Feb; 48(2):129-37. PubMed ID: 20137765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany.
    Pscherer S; Dietrich ES; Dippel FW; Neilson AR
    Ger Med Sci; 2010 Aug; 8():. PubMed ID: 20725588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study].
    Bierwirth RA; Kohlmann T; Moock J; Holle R; Landgraf W
    Med Klin (Munich); 2010 Nov; 105(11):792-801. PubMed ID: 21136237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.